Beth Overmoyer
Impact in
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
Papers in
-
- Breast Cancer Treatment Studies 57
- Cancer Genomics and Diagnostics 12
- Oncology 106
- Cancer Treatment and Pharmacology 44
- HER2/EGFR in Cancer Research 39
- Cancer Immunotherapy and Biomarkers 16
- Co-authors
- P. Kelly MarcomHope S. RugoEric P. WinerKathy D. MillerLinnea ChapAfshin DowlatiFrankie A. HolmesLouis Fehrenbacher
- Journals
- Journal of Clinical Oncology (31 papers)Cancer Research (21 papers)Breast Cancer Research and Treatment (11 papers)Bone Marrow Transplantation (7 papers)Clinical Breast Cancer (6 papers)
- Partner nations
- United StatesBrazilUnited Kingdom
In The Last Decade
Beth Overmoyer
140 papers receiving 6.0k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Oncology 4.4k
- Cancer Research 1.9k
- Pulmonary and Respiratory Medicine 1.3k
- Genetics 412
- Radiology, Nuclear Medicine and Imaging 884
Countries citing papers authored by Beth Overmoyer
This map shows the geographic impact of Beth Overmoyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Overmoyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Overmoyer more than expected).
Fields of papers citing papers by Beth Overmoyer
This network shows the impact of papers produced by Beth Overmoyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Overmoyer. The network helps show where Beth Overmoyer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Beth Overmoyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 20 | |
| 2 | 2023 | 0 | |
| 3 | 2022 | 31 | |
| 4 | 2022 | 16 | |
| 5 | 2022 | 15 | |
| 6 | 2021 | 9 | |
| 7 | 2021 | 0 | |
| 8 | 2020 | 19 | |
| 9 | 2019 | 1 | |
| 10 | 2018 | 58 | |
| 11 | 2017 | 4 | |
| 12 | 2016 | 60 | |
| 13 | 2015 | 26 | |
| 14 | 2008 | 89 | |
| 15 | Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas Hit paper breakdown → | 2005 | 503 |
| 16 | 2005 | 290 | |
| 17 | A phase I pharmacokinetic and pharmacodynamic study of SU5416 and Adriamycin in inflammatory breast cancer | 2001 | 13 |
| 18 | 1999 | 14 | |
| 19 | 1998 | 4 | |
| 20 | 1998 | 39 |
About Beth Overmoyer
Beth Overmoyer is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Hematology, having authored 143 papers that have together received 6.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (57 papers), Cancer Treatment and Pharmacology (44 papers), HER2/EGFR in Cancer Research (39 papers), Advanced Breast Cancer Therapies (29 papers), Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (13 papers), Breast Lesions and Carcinomas (13 papers) and Cancer Genomics and Diagnostics (12 papers). The work is most often cited by research in Oncology (4.4k citations), Cancer Research (1.9k citations), Pulmonary and Respiratory Medicine (1.3k citations), Genetics (412 citations) and Radiology, Nuclear Medicine and Imaging (884 citations). Beth Overmoyer has collaborated with scholars based in United States, Brazil and United Kingdom. Frequent co-authors include P. Kelly Marcom, Hope S. Rugo, Eric P. Winer, Kathy D. Miller, Linnea Chap, Afshin Dowlati, Frankie A. Holmes, Louis Fehrenbacher, Melody Cobleigh and Amy P. Sing. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Bone Marrow Transplantation and Clinical Breast Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.